[go: up one dir, main page]

BR112021022722A2 - Animal não humano, célula de animal não humana, genoma de animal não humano, gene de albumina animal não humana humanizada, vetor de alvejamento, método de avaliação da atividade de um reagente, e, método de otimização da atividade de um reagente - Google Patents

Animal não humano, célula de animal não humana, genoma de animal não humano, gene de albumina animal não humana humanizada, vetor de alvejamento, método de avaliação da atividade de um reagente, e, método de otimização da atividade de um reagente

Info

Publication number
BR112021022722A2
BR112021022722A2 BR112021022722A BR112021022722A BR112021022722A2 BR 112021022722 A2 BR112021022722 A2 BR 112021022722A2 BR 112021022722 A BR112021022722 A BR 112021022722A BR 112021022722 A BR112021022722 A BR 112021022722A BR 112021022722 A2 BR112021022722 A2 BR 112021022722A2
Authority
BR
Brazil
Prior art keywords
human animal
human
reagent
activity
albumin
Prior art date
Application number
BR112021022722A
Other languages
English (en)
Inventor
Brian Zambrowicz
Chia-Jen Siao
Dan Chalothorn
Kehdih Lai
Leah Sabin
Lori Morton
Qing Fang
Rachel Sattler
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112021022722A2 publication Critical patent/BR112021022722A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

animal não humano, célula de animal não humana, genoma de animal não humano, gene de albumina animal não humana humanizada, vetor de alvejamento, método de avaliação da atividade de um reagente, e, método de otimização da atividade de um reagente. são fornecidos genomas de animais não humanos, células de animais não humanos, e animais não humanos que compreendem um locus de albumina (alb) humanizada, e métodos para fabricação e uso de tais genomas de animais não humanos, células de animais não humanos, e animais não humanos. células de animais não humanos, ou animais não humanos, que compreendem um locus de albumina humanizada expressam uma proteína albumina humana ou uma proteína albumina quimérica, fragmentos das quais são de albumina humana. métodos são fornecidos para o uso de tais animais não humanos que compreendem um locus de albumina humanizada para avaliar a eficácia in vivo de reagentes de alvejamento de albumina humana, tais como agentes de nuclease concebidos para alvejar a albumina humana.
BR112021022722A 2019-06-07 2020-06-05 Animal não humano, célula de animal não humana, genoma de animal não humano, gene de albumina animal não humana humanizada, vetor de alvejamento, método de avaliação da atividade de um reagente, e, método de otimização da atividade de um reagente BR112021022722A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962858589P 2019-06-07 2019-06-07
US201962916666P 2019-10-17 2019-10-17
PCT/US2020/036412 WO2020247812A1 (en) 2019-06-07 2020-06-05 Non-human animals comprising a humanized albumin locus

Publications (1)

Publication Number Publication Date
BR112021022722A2 true BR112021022722A2 (pt) 2022-01-04

Family

ID=71899847

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022722A BR112021022722A2 (pt) 2019-06-07 2020-06-05 Animal não humano, célula de animal não humana, genoma de animal não humano, gene de albumina animal não humana humanizada, vetor de alvejamento, método de avaliação da atividade de um reagente, e, método de otimização da atividade de um reagente

Country Status (13)

Country Link
US (2) US11622547B2 (pt)
EP (1) EP3796776A1 (pt)
JP (1) JP7698587B2 (pt)
KR (1) KR102783949B1 (pt)
CN (1) CN113939595A (pt)
AU (1) AU2020289581B2 (pt)
BR (1) BR112021022722A2 (pt)
CA (1) CA3137764A1 (pt)
IL (1) IL288606B2 (pt)
MX (1) MX2021015122A (pt)
SG (1) SG11202111256XA (pt)
TW (1) TW202112229A (pt)
WO (1) WO2020247812A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018338790B2 (en) 2017-09-29 2022-09-15 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized TTR locus and methods of use
IL286905B2 (en) 2019-04-04 2024-06-01 Regeneron Pharma Non-human animals containing the human coagulation factor 12 locus
KR20220016869A (ko) 2019-06-04 2022-02-10 리제너론 파마슈티칼스 인코포레이티드 베타-슬립 돌연변이를 갖는 인간화 ttr 좌위를 포함하는 비-인간 동물 및 사용 방법
BR112021022722A2 (pt) 2019-06-07 2022-01-04 Regeneron Pharma Animal não humano, célula de animal não humana, genoma de animal não humano, gene de albumina animal não humana humanizada, vetor de alvejamento, método de avaliação da atividade de um reagente, e, método de otimização da atividade de um reagente

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
AU8587598A (en) 1997-07-26 1999-02-16 Wisconsin Alumni Research Foundation Trans-species nuclear transfer
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US20030104526A1 (en) 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2004537260A (ja) 2000-12-07 2004-12-16 サンガモ バイオサイエンシーズ， インコーポレイテッド ジンクフィンガータンパク質による血管新生の調節
US7273923B2 (en) 2001-01-22 2007-09-25 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
AU2002225187A1 (en) 2001-01-22 2002-07-30 Sangamo Biosciences, Inc. Zinc finger polypeptides and their use
AUPR446701A0 (en) * 2001-04-18 2001-05-17 Gene Stream Pty Ltd Transgenic mammals for pharmacological and toxicological studies
AUPR451401A0 (en) 2001-04-20 2001-05-24 Monash University A method of nuclear transfer
BRPI0307383B1 (pt) 2002-01-23 2019-12-31 The Univ Of Utah Research Foundation método de recombinação genética direcionada em célula de planta hospedeira
CA2479153C (en) 2002-03-15 2015-06-02 Cellectis Hybrid and single chain meganucleases and use thereof
AU2003218382B2 (en) 2002-03-21 2007-12-13 Sangamo Therapeutics, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US7612250B2 (en) 2002-07-29 2009-11-03 Trustees Of Tufts College Nuclear transfer embryo formation method
JP2006502748A (ja) 2002-09-05 2006-01-26 カリフォルニア インスティテュート オブ テクノロジー 遺伝子ターゲッティングを誘発するキメラヌクレアーゼの使用方法
AU2003290518A1 (en) 2002-09-06 2004-04-23 Fred Hutchinson Cancer Research Center Methods and compositions concerning designed highly-specific nucleic acid binding proteins
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EP1591521A1 (en) 2004-04-30 2005-11-02 Cellectis I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof
EP2292274A1 (en) 2004-09-16 2011-03-09 Sangamo BioSciences, Inc. Compositions and methods for protein production
ES2667169T3 (es) 2004-10-19 2018-05-09 Regeneron Pharmaceuticals, Inc. Método para generar un animal no humano homocigótico para una modificación genética
ATE466933T1 (de) 2005-03-15 2010-05-15 Cellectis I-crei-meganuklease-varianten mit modifizierter spezifität sowie verfahren zu ihrer herstellung und verwendung
WO2006097784A1 (en) 2005-03-15 2006-09-21 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
CN101117633B (zh) 2006-08-03 2011-07-20 上海交通大学附属儿童医院 一种细胞核移植方法
US9187758B2 (en) 2006-12-14 2015-11-17 Sangamo Biosciences, Inc. Optimized non-canonical zinc finger proteins
US20110020722A1 (en) 2008-04-11 2011-01-27 Lake Jeffrey G Fuel cell and bipolar plate having manifold sump
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
WO2010107493A2 (en) 2009-03-20 2010-09-23 Sangamo Biosciences, Inc. Modification of cxcr4 using engineered zinc finger proteins
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
WO2011017293A2 (en) 2009-08-03 2011-02-10 The General Hospital Corporation Engineering of zinc finger arrays by context-dependent assembly
US8518392B2 (en) 2009-08-14 2013-08-27 Regeneron Pharmaceuticals, Inc. Promoter-regulated differentiation-dependent self-deleting cassette
PT3056082T (pt) 2009-10-06 2018-12-12 Univ Yale Ratinhos modificados geneticamente e enxerto
PL2494047T3 (pl) 2009-10-29 2017-05-31 Regeneron Pharmaceuticals, Inc. Allele wielofunkcyjne
EP3456826B1 (en) 2009-12-10 2023-06-28 Regents of the University of Minnesota Tal effector-mediated dna modification
EP2675271B1 (en) 2011-02-15 2018-06-13 Regeneron Pharmaceuticals, Inc. Humanized m-csf mice
EP2718319B1 (en) 2011-06-07 2017-12-06 Wisconsin Alumni Research Foundation Hepatocyte based insulin gene therapy for diabetes
US9394545B2 (en) 2011-09-21 2016-07-19 Sangamo Biosciences, Inc. Methods and compositions for regulation of transgene expression
MY172726A (en) 2011-10-28 2019-12-11 Regeneron Pharma Humanized il-6 and il-6 receptor
CA2850387A1 (en) 2011-10-28 2013-05-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
EP3839050A3 (en) 2012-04-18 2021-09-29 The Board of Trustees of the Leland Stanford Junior University Non-disruptive gene targeting
EP2847335B1 (en) 2012-04-25 2018-06-27 Regeneron Pharmaceuticals, Inc. Nuclease-mediated targeting with large targeting vectors
LT2800811T (lt) 2012-05-25 2017-09-11 The Regents Of The University Of California Būdai ir kompozicijos, skirti tikslinės dnr modifikavimui, panaudojant adresuotą rnr, ir transkripcijos moduliavimui, panaudojant adresuotą rnr
US8962913B2 (en) 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
WO2014011237A1 (en) 2012-07-11 2014-01-16 Sangamo Biosciences, Inc. Methods and compositions for the treatment of lysosomal storage diseases
US10648001B2 (en) 2012-07-11 2020-05-12 Sangamo Therapeutics, Inc. Method of treating mucopolysaccharidosis type I or II
WO2014033644A2 (en) 2012-08-28 2014-03-06 Novartis Ag Methods of nuclease-based genetic engineering
AU2013335451C1 (en) 2012-10-23 2024-07-04 Toolgen Incorporated Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof
IL311744B1 (en) 2012-11-05 2025-06-01 Regeneron Pharma Genetically modified non-human animals and methods of using them
CA2892448A1 (en) 2012-12-05 2014-06-12 Sangamo Biosciences, Inc. Methods and compositions for regulation of metabolic disorders
EP3138911B1 (en) 2012-12-06 2018-12-05 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US20140179770A1 (en) 2012-12-12 2014-06-26 Massachusetts Institute Of Technology Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
SG10201704932UA (en) 2012-12-17 2017-07-28 Harvard College Rna-guided human genome engineering
CA2900992C (en) 2013-02-20 2023-02-28 Regeneron Pharmaceuticals, Inc. Genetic modification of rats
CN105164154B (zh) 2013-02-22 2019-06-07 瑞泽恩制药公司 表达人源化主要组织相容性复合物的小鼠
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
EP2922393B2 (en) 2013-02-27 2022-12-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Gene editing in the oocyte by cas9 nucleases
US9885033B2 (en) 2013-03-15 2018-02-06 The General Hospital Corporation Increasing specificity for RNA-guided genome editing
JP2016522679A (ja) 2013-04-04 2016-08-04 プレジデント アンド フェローズ オブ ハーバード カレッジ ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
PL3456831T3 (pl) 2013-04-16 2021-12-06 Regeneron Pharmaceuticals, Inc. Ukierunkowana modyfikacja genomu szczura
JP2016518142A (ja) 2013-05-10 2016-06-23 サンガモ バイオサイエンシーズ， インコーポレイテッド ヌクレアーゼ媒介ゲノム遺伝子操作のための送達方法および組成物
EP3730615A3 (en) 2013-05-15 2020-12-09 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
KR20160030187A (ko) 2013-06-17 2016-03-16 더 브로드 인스티튜트, 인코퍼레이티드 간의 표적화 및 치료를 위한 ＣＲＩＳＰＲ­Ｃａｓ 시스템, 벡터 및 조성물의 전달 및 용도
PL3434101T3 (pl) 2013-09-23 2024-02-19 Regeneron Pharmaceuticals, Inc. Zwierzęta inne niż ludzie posiadające humanizowany gen białka regulacji sygnału
US20160237455A1 (en) 2013-09-27 2016-08-18 Editas Medicine, Inc. Crispr-related methods and compositions
RS55472B1 (sr) 2013-10-15 2017-04-28 Regeneron Pharma Životinje sa humanizovanim il-15
EP3058072B1 (en) 2013-10-17 2021-05-19 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
AU2014364051B2 (en) 2013-12-09 2018-12-20 Sangamo Therapeutics, Inc. Methods and compositions for treating hemophilia
SMT201800653T1 (it) * 2013-12-11 2019-01-11 Regeneron Pharma Metodi e composizioni per la modificazione indirizzata a bersaglio di un genoma
MX388127B (es) 2013-12-11 2025-03-19 Regeneron Pharma Metodos y composiciones para la modificacion dirigida de un genoma.
EP3079726B1 (en) 2013-12-12 2018-12-05 The Broad Institute, Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
WO2015127439A1 (en) 2014-02-24 2015-08-27 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated targeted integration
CN106460009A (zh) 2014-03-21 2017-02-22 小利兰·斯坦福大学托管委员会 无核酸酶的基因组编辑
CA3225091A1 (en) 2014-05-05 2015-11-12 Regeneron Pharmaceuticals, Inc. Humanized c5 and c3 animals
NO2785538T3 (pt) 2014-05-07 2018-08-04
KR102627332B1 (ko) 2014-05-19 2024-01-26 리제너론 파마슈티칼스 인코포레이티드 인간 epo를 발현하는 유전자 변형된 비-인간 동물
EP3155116A4 (en) 2014-06-10 2017-12-27 Massachusetts Institute Of Technology Method for gene editing
SG11201610405RA (en) 2014-06-16 2017-01-27 Univ Johns Hopkins Compositions and methods for the expression of crispr guide rnas using the h1 promoter
NZ765591A (en) 2014-06-23 2022-09-30 Regeneron Pharma Nuclease-mediated dna assembly
US20150376586A1 (en) 2014-06-25 2015-12-31 Caribou Biosciences, Inc. RNA Modification to Engineer Cas9 Activity
US9902971B2 (en) 2014-06-26 2018-02-27 Regeneron Pharmaceuticals, Inc. Methods for producing a mouse XY embryonic (ES) cell line capable of producing a fertile XY female mouse in an F0 generation
JP6778175B2 (ja) 2014-07-16 2020-10-28 ノバルティス アーゲー 脂質ナノ粒子ホスト中に核酸を封入する方法
CN107072184A (zh) 2014-09-19 2017-08-18 瑞泽恩制药公司 嵌合抗原受体
EP3521437B1 (en) 2014-11-21 2025-01-15 Regeneron Pharmaceuticals, Inc. Methods for targeted genetic modification using paired guide rnas
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
KR102699643B1 (ko) 2015-04-06 2024-08-28 리제너론 파아마슈티컬스, 인크. 비인간 동물에서의 인간화 t 세포 매개 면역반응
US10626393B2 (en) 2015-06-04 2020-04-21 Arbutus Biopharma Corporation Delivering CRISPR therapeutics with lipid nanoparticles
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
CN108024544B (zh) 2015-07-13 2022-04-29 桑格摩生物治疗股份有限公司 用于核酸酶介导的基因组工程化的递送方法及组合物
EP3159407A1 (en) 2015-10-23 2017-04-26 Silence Therapeutics (London) Ltd Guide rnas, methods and uses
AU2016343887B2 (en) 2015-10-28 2023-04-06 Sangamo Therapeutics, Inc. Liver-specific constructs, factor VIII expression cassettes and methods of use thereof
CA2999649A1 (en) 2015-11-06 2017-05-11 Crispr Therapeutics Ag Materials and methods for treatment of glycogen storage disease type 1a
ES2872799T3 (es) 2015-11-20 2021-11-02 Regeneron Pharma Animales no humanos que tienen un gen 3 de activación linfocitaria humanizado
AU2016361350B2 (en) 2015-11-23 2023-04-06 Sangamo Therapeutics, Inc. Methods and compositions for engineering immunity
CN109715801B (zh) 2015-12-01 2022-11-01 克里斯普治疗股份公司 用于治疗α1抗胰蛋白酶缺乏的材料和方法
MX2018007840A (es) 2015-12-23 2019-05-02 Crispr Therapeutics Ag Materiales y metodos para el tratamiento de la esclerosis lateral amiotrofica y/o la degeneracion lobar frontotemporal.
US20190038771A1 (en) 2016-02-02 2019-02-07 Crispr Therapeutics Ag Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
ES2908669T3 (es) 2016-02-04 2022-05-03 Regeneron Pharma Animales no humanos que tienen un gen ANGPTL8 modificado genéticamente
EP3416689B1 (en) 2016-02-18 2023-01-18 CRISPR Therapeutics AG Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
US11083799B2 (en) 2016-03-16 2021-08-10 Crispr Therapeutics Ag Materials and methods for treatment of hereditary haemochromatosis
FI3436077T3 (fi) 2016-03-30 2025-07-10 Intellia Therapeutics Inc Lipidinanopartikkeliformulaatioita crispr/cas-komponenteille
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
US11427838B2 (en) 2016-06-29 2022-08-30 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
WO2018007871A1 (en) 2016-07-08 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of transthyretin amyloidosis
WO2018013932A1 (en) 2016-07-15 2018-01-18 Salk Institute For Biological Studies Methods and compositions for genome editing in non-dividing cells
JP7042263B2 (ja) 2016-10-20 2022-03-25 サンガモ セラピューティクス， インコーポレイテッド ファブリー病の治療のための方法および組成物
CN119464289A (zh) 2016-12-08 2025-02-18 因特利亚治疗公司 经修饰的指导rna
JP2020500539A (ja) 2016-12-09 2020-01-16 サンガモ セラピューティクス， インコーポレイテッド 標的特異的ヌクレアーゼの送達
WO2018126087A1 (en) 2016-12-29 2018-07-05 Applied Stemcell, Inc. Gene editing method using virus
US11407997B2 (en) 2017-02-22 2022-08-09 Crispr Therapeutics Ag Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders
CN110494168B (zh) 2017-02-27 2023-02-03 再生元制药公司 肾病症和肝病症的人源化模型
CA3067316A1 (en) 2017-06-15 2018-12-20 Toolgen Incorporated Platform for expressing protein of interest in liver
US11981898B2 (en) 2017-06-16 2024-05-14 Applied Stemcell, Inc. Gene editing methods with increased knock-in efficiency
AU2018338790B2 (en) 2017-09-29 2022-09-15 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized TTR locus and methods of use
AU2018353012B2 (en) 2017-10-17 2025-03-27 Bayer Healthcare Llc Compositions and methods for gene editing for Hemophilia A
US20190153440A1 (en) 2017-11-21 2019-05-23 Casebia Therapeutics Llp Materials and methods for treatment of autosomal dominant retinitis pigmentosa
MX2020005808A (es) 2017-12-06 2020-10-28 Generation Bio Co Edición de genes mediante el uso de un adn modificado de extremo cerrado (ceadn).
US20230201373A1 (en) 2017-12-15 2023-06-29 Regents Of The University Of Minnesota Crispr-mediated genome editing with vectors
WO2019134561A1 (en) 2018-01-05 2019-07-11 The Chinese University Of Hong Kong High efficiency in vivo knock-in using crispr
CA3088180A1 (en) 2018-01-12 2019-07-18 Crispr Therapeutics Ag Compositions and methods for gene editing by targeting transferrin
EP3752616A1 (en) 2018-02-16 2020-12-23 CRISPR Therapeutics AG Compositions and methods for gene editing by targeting fibrinogen-alpha
KR20210004994A (ko) 2018-03-26 2021-01-13 리제너론 파마슈티칼스 인코포레이티드 치료제를 시험하기 위한 인간화된 설치류
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
KR20210029772A (ko) 2018-06-08 2021-03-16 인텔리아 테라퓨틱스, 인크. 유전자 편집을 위한 변형된 가이드 rna
JP2021528426A (ja) 2018-06-19 2021-10-21 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ｍＲＮＡおよび長い核酸の送達のための脂質ナノ粒子組成物
WO2020006132A1 (en) 2018-06-27 2020-01-02 Altius Institute For Biomedical Sciences Gapped and tunable repeat units for use in genome editing and gene regulation compositions
WO2020006126A1 (en) 2018-06-27 2020-01-02 Altius Institute For Biomedical Sciences Nucleic acid binding domains and methods of use thereof
WO2020006131A2 (en) 2018-06-27 2020-01-02 Altius Institute For Biomedical Sciences Nucleases for genome editing
IL315703A (en) 2018-07-16 2024-11-01 Regeneron Pharma Non-human animal models of DITRA disease and their uses
CN113166748A (zh) 2018-08-10 2021-07-23 逻辑生物治疗公司 用于治疗mma的非破坏性基因疗法
CN113348247A (zh) 2018-10-15 2021-09-03 泰莱托恩基金会 基因组编辑方法与构建体
CA3116885A1 (en) 2018-10-17 2020-04-23 Crispr Therapeutics Ag Compositions and methods for delivering transgenes
TW202028461A (zh) 2018-10-18 2020-08-01 美商英特利亞醫療公司 核酸構築體及使用方法
SG11202103734PA (en) 2018-10-18 2021-05-28 Intellia Therapeutics Inc Compositions and methods for expressing factor ix
WO2020082047A1 (en) 2018-10-18 2020-04-23 Intellia Therapeutics, Inc. Compositions and methods for treating alpha-1 antitrypsin deficiencey
TW202507011A (zh) 2018-10-18 2025-02-16 美商英特利亞醫療公司 用於從白蛋白基因座表現轉殖基因的組成物及方法
CA3121191A1 (en) 2018-11-28 2020-06-04 Crispr Therapeutics Ag Optimized mrna encoding cas9 for use in lnps
MA54951A (fr) 2019-02-15 2021-12-22 Bayer Healthcare Llc Édition de gène pour l'hémophilie a avec une expression de facteur viii améliorée
KR20210148154A (ko) 2019-04-03 2021-12-07 리제너론 파마슈티칼스 인코포레이티드 세이프 하버 좌위 내로의 항체 코딩 서열의 삽입을 위한 방법 및 조성물
IL286905B2 (en) 2019-04-04 2024-06-01 Regeneron Pharma Non-human animals containing the human coagulation factor 12 locus
US11702644B2 (en) 2019-04-11 2023-07-18 California Institute Of Technology Methods and compositions for in vivo gene editing based cell-type-specific cellular engineering
KR20220015385A (ko) 2019-05-30 2022-02-08 국립대학법인 홋가이도 다이가쿠 지질 나노 입자
KR20220016869A (ko) 2019-06-04 2022-02-10 리제너론 파마슈티칼스 인코포레이티드 베타-슬립 돌연변이를 갖는 인간화 ttr 좌위를 포함하는 비-인간 동물 및 사용 방법
BR112021022722A2 (pt) 2019-06-07 2022-01-04 Regeneron Pharma Animal não humano, célula de animal não humana, genoma de animal não humano, gene de albumina animal não humana humanizada, vetor de alvejamento, método de avaliação da atividade de um reagente, e, método de otimização da atividade de um reagente
WO2021072115A1 (en) 2019-10-08 2021-04-15 Regents Of The University Of Minnesota Crispr-mediated human genome editing with vectors
WO2021083073A1 (zh) 2019-10-31 2021-05-06 华东师范大学 一种基于肝细胞Alb基因的疾病治疗的产品
EP4146284A1 (en) 2020-05-06 2023-03-15 Cellectis S.A. Methods to genetically modify cells for delivery of therapeutic proteins
MX2024004244A (es) 2021-10-07 2024-04-24 Procter & Gamble Composicion de champu acondicionador libre de sulfato que contiene un polimero cationico y sal inorganica.

Also Published As

Publication number Publication date
CA3137764A1 (en) 2020-12-10
IL288606B2 (en) 2024-12-01
US11622547B2 (en) 2023-04-11
JP7698587B2 (ja) 2025-06-25
IL288606B1 (en) 2024-08-01
JP2022534560A (ja) 2022-08-02
MX2021015122A (es) 2022-04-06
KR102783949B1 (ko) 2025-03-21
US20230232797A1 (en) 2023-07-27
US20200383304A1 (en) 2020-12-10
AU2020289581B2 (en) 2024-11-21
IL288606A (en) 2022-02-01
TW202112229A (zh) 2021-04-01
SG11202111256XA (en) 2021-11-29
US12317874B2 (en) 2025-06-03
CN113939595A (zh) 2022-01-14
EP3796776A1 (en) 2021-03-31
AU2020289581A1 (en) 2021-11-18
WO2020247812A1 (en) 2020-12-10
KR20220017939A (ko) 2022-02-14

Similar Documents

Publication Publication Date Title
BR112021022722A2 (pt) Animal não humano, célula de animal não humana, genoma de animal não humano, gene de albumina animal não humana humanizada, vetor de alvejamento, método de avaliação da atividade de um reagente, e, método de otimização da atividade de um reagente
MX394999B (es) Animales no humanos que comprenden un locus ttr humanizado y metodos de uso
BR112021019512A2 (pt) Métodos para inserir uma sequência de codificação de proteína de ligação ao antígeno e para tratar ou efetuar a profilaxia de uma doença em um animal, animal, célula, genoma, ácido nucleico doador exógeno, gene de porto seguro, e, agente de nuclease ou um ou mais ácidos nucleicos
Underwood et al. Biology and diseases of ruminants (sheep, goats, and cattle)
BR112017010490A2 (pt) roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano.
CL2024002913A1 (es) Editores de nucleobase que comprende proteina de union a adn programable de acido nucleico.
BR112018006531A2 (pt) proteína isolada de ligação ao antígeno (abp), polinucleotídeo isolado, vetor, célula hospedeira, método para produzir uma proteína isolada de ligação ao antígeno (abp), composição farmacêutica, método para tratar ou prevenir uma doença ou condição num sujeito em necessidade deste, método para modular uma resposta imune num indivíduo em necessidade deste e kit
PH12021550843A1 (en) Nucleic acid constructs and methods of use
PH12016502058A1 (en) Humanized il-4 and il-4r alpha animals
MX2021004391A (es) Proteinas inteinas y usos de las mismas.
BR112017018728A2 (pt) sistema de vetor para expressar a sequência de codificação de um gene de interesse em uma célula, célula hospedeira, composição farmacêutica, método para tratar e/ou prevenir uma patologia ou doença, uso de uma sequência de nucleotídeo de um sinal de degradação em um sistema de vetor e método para diminuir a expressão de uma proteína na forma truncada
BR112014018843A8 (pt) métodos para obter um animal não humano, para produzir uma protéina e para modificar um locus de cadeia pesada de imunoglobulina de um roedor, e, hibridoma
BR112018009098A8 (pt) métodos e composições para edição genética em células-tronco hematopoiéticas
BR112016011004A2 (pt) animal roedor geneticamente modificado, célula tronco embrionária de roedor, embrião de roedor, e, métodos para fabricar um animal roedor e para enxertar células humanas em um camundongo
BR112016029650A2 (pt) roedor, polipeptídeo pd-1, célula isolada ou tecido de roedor, célula-tronco embrionária de roedor, métodos de produzir um roedor, de reduzir o crescimento de tumor em um roedor, de matar células tumorais em um roedor e de avaliar as propriedades farmacocinéticas de uma droga que direciona pd-1 humano, e, modelo de tumor de roedor?
MX2018001617A (es) Composiciones de crispr-cas9 diseñados y metodos de uso.
MX2020004803A (es) Animales con dipeptidil peptidasa iv (dpp4) humanizada.
BR112016025751A2 (pt) roedor, e, métodos para fabricar um roedor e um camundongo humanizados e para identificar um composto capaz de modular a ativação de complemento
BR112014029441A2 (pt) rna tendo como alvo dna; polinucleotídeo de dna; vetor de expressão recombinante; célula hospedeira geneticamente modificada in vitro; polipeptídeo de modificação dirigido a sítio variante; polipeptídeo de modificação dirigido a sítio quimérico; polinucleotídeo de rna; célula modificada geneticamente; organismo não humano transgênico cujo genoma compreende um transgene; composição; método de modificação específica de sítio de um dna de alvo; método de modulação de transcrição específica de sítio dentro de um dna de alvo; método de modificação específica de sítio em dna de alvo; método de promover clivagem e modificação específica de sítio de um dna de alvo em uma célula; método de produzir uma célula modificada geneticamente em um sujeito; método de modificar dna de alvo em uma célula modificada geneticamente; kit; kit para direcionar dna de alvo; método de modular seletivamente transcrição de um dna de alvo em uma célula hospedeira; ácido nucleico isolado; célula hospedeira modificada geneticamente; e biblioteca de ácidos nucleicos
BR112015002280A2 (pt) produção de gado resistente a vfa por substituição de alelo
BR112017025929A2 (pt) genes pesticidas e métodos de uso
BR112016002385A2 (pt) animal não humano, célula, tecido ou embrião, vetor de alvejamento, constructo de vetor de alvejamento, e, métodos para produzir um animal não humano e para modificar um lócus de incrna em uma célula pluripotente
BR112022007375A2 (pt) Sequenciamento de tecido intacto em escala clínica e industrial
WO2020206139A9 (en) Non-human animals comprising a humanized coagulation factor 12 locus
EP4484562A3 (en) Non-human animals comprising a humanized asgr1 locus

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements